# A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P

Source: https://onco.cc/trials/nct06581406/  
OnCo record `nct06581406` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Ipilimumab, Nivolumab in melanoma and uveal melanoma, run by Replimune, Inc., now recruiting.

## Summary

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma is a phase 2/3 interventional study registered as NCT06581406 by Replimune, Inc., with 280 participants planned, started 2024-12-17 and due to reach its primary completion in 2030-01. Interventions recorded: RP2, Ipilimumab, Nivolumab. Conditions listed: Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06581406
- Phase: 2/3
- Setting: A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Sponsor: Replimune, Inc.
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT06581406: https://clinicaltrials.gov/study/NCT06581406

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Replimune](https://onco.cc/companies/replimune/)

---
JSON: https://onco.cc/api/v1/entities/nct06581406.json